Phase II Study of Tesetaxel in Metastatic Melanoma
Completed
Genta Incorporated
Phase 2
The goal of this clinical research study is to learn if tesetaxel can help to control
metastatic melanoma. The safety of this drug will also be studied.
Phase II Study of Tesetaxel in Metastatic Melanoma
Completed
M.D. Anderson Cancer Center
Phase 2
The goal of this clinical research study is to learn if tesetaxel can help to control
metastatic melanoma. The safety of this drug will also be studied.
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Unknown status
Genta Incorporated
Phase 2
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is
being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line
therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Unknown status
Genta Incorporated
Phase 2
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is
being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line
therapy to patients with advanced gastric cancer.
Tesetaxel for Previously Treated Patients With Bladder Cancer
Unknown status
Genta Incorporated
Phase 2
The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination
with other chemotherapy agents are active in patients with advanced and metastatic bladder
cancer, and agents of this class are a promising treatment option for some patients.
Tesetaxel is an orally administered taxane that is in development as treatment for subjects
with advanced cancers. This study is being conducted to determine the efficacy and safety of
tesetaxel administered to patients previously treated with chemotherapy for progressive
metastatic transitional cell carcinoma of the urothelium.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
